NeutriSci International Inc. (NRXCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NeutriSci International Inc. (NRXCF) with AI Score 56/100 (Grade B). NeutriSci International Inc. develops and distributes nutraceutical products, primarily the neuenergy energy tablet, across multiple continents. Sector: Healthcare.
Last analyzed: Jun 14, 2026NRXCF: 2/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →NeutriSci International Inc. (NRXCF) Healthcare & Pipeline Overview
NeutriSci International Inc. is a Canadian nutraceutical company specializing in the development and global distribution of innovative dietary supplements, including its flagship neuenergy tablet. Leveraging oral thin film technology, it aims to capture market share in the growing consumer health sector through a diverse distribution network and strategic partnerships.
What Is the Investment Thesis for NRXCF?
NeutriSci International Inc. presents an investment profile centered on its participation in the growing nutraceutical market and its focus on innovative product delivery. The company's core asset, neuenergy, addresses consumer demand for cognitive enhancement and energy, distributed across Canada, the U.S., Europe, Asia, and South America. A key value driver is the company's commitment to oral thin film technology, which could offer a competitive advantage through enhanced absorption and user convenience, potentially attracting a broader consumer base. Growth catalysts include the successful expansion of its distribution network, the leveraging of existing partnerships with LaSanta Botanicals, Nutritional High, and Naturally Splendid, and the potential for new strategic alliances to broaden its product portfolio or market reach. However, the company operates with significant financial challenges, evidenced by a market capitalization of $0.00B, a profit margin of -168.4%, and a gross margin of -9.5%. These metrics indicate substantial unprofitability and operational inefficiencies that pose considerable risks. Its classification as an OTC Other tier stock implies limited liquidity and potentially less stringent reporting, increasing investment risk. Future profitability hinges on the company's ability to scale production efficiently, manage costs, and convert its product innovation into sustainable revenue streams within a highly competitive market.
Based on FMP financials and quantitative analysis
NRXCF Key Highlights
- Market Capitalization: The company currently holds a market capitalization of $0.00B, reflecting a very small public valuation and potentially limited investor interest or market liquidity.
- Profitability Challenges: NeutriSci reported a profit margin of -168.4%, indicating substantial net losses relative to its revenue and significant challenges in achieving financial viability.
- Negative Gross Margin: A gross margin of -9.5% suggests that the cost of goods sold exceeds revenue, highlighting fundamental issues in product pricing, production efficiency, or supply chain management.
- Global Distribution Network: NeutriSci distributes its nutraceutical products across Canada, the United States, Europe, Asia, and South America, demonstrating a broad geographic ambition despite its current financial scale.
- Innovative Product Focus: The company emphasizes its neuenergy energy tablet and the development of oral thin film technology for enhanced absorption, positioning itself in the market with a focus on product innovation and consumer convenience.
Who Are NRXCF's Competitors?
NRXCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NRXCF's Key Strengths?
- Global distribution network spanning Canada, US, Europe, Asia, and South America.
- Focus on innovative oral thin film technology for enhanced product delivery.
- Strategic partnerships with industry players like LaSanta Botanicals and Nutritional High.
- Proprietary product 'neuenergy' addressing a specific consumer need for focus and clarity.
What Are NRXCF's Weaknesses?
- Market capitalization of $0.00B indicates extremely limited scale and investor confidence.
- Significant unprofitability with a profit margin of -168.4% and negative gross margin of -9.5%.
- Reliance on a single flagship product (neuenergy) for a substantial portion of its revenue.
- Operating in the OTC Other tier, which implies potentially limited liquidity and disclosure.
What Could Drive NRXCF Stock Higher?
- Successful securing of new strategic partnerships to expand product lines or distribution channels, potentially leading to increased revenue streams and market reach.
- Achievement of significant operational efficiencies and cost reductions, which could improve the company's currently negative gross and profit margins.
- Introduction of new nutraceutical products utilizing the oral thin film technology, expanding the company's portfolio beyond neuenergy and tapping into new market segments.
- Expansion of the retail and online distribution network in existing or new international markets, driving increased sales volume for its current product offerings.
- Positive market reception and increased consumer adoption of its innovative oral thin film delivery system, enhancing brand reputation and competitive positioning.
What Are the Key Risks for NRXCF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Persistent unprofitability, as evidenced by a profit margin of -168.4% and a gross margin of -9.5%, which poses a significant threat to long-term operational sustainability.
- High competition within the fragmented nutraceutical market from larger, more established players with greater resources for R&D, marketing, and distribution.
- Limited liquidity and transparency due to its OTC Other tier classification and 'Unknown' disclosure status, making it challenging for investors to trade shares or assess company health.
- Failure to secure additional funding or achieve profitability, which could lead to further operational constraints or potential business cessation.
- Regulatory challenges and compliance costs associated with operating and distributing nutraceutical products across diverse international markets, which can impact product approval and market access.
What Are the Growth Opportunities for NRXCF?
- Expansion of Oral Thin Film Technology Applications: NeutriSci's focus on oral thin film technology represents a significant growth avenue. This innovative delivery system, designed for enhanced absorption and convenience, can be applied to a broader range of nutraceuticals beyond just energy tablets. The global market for oral thin films is projected to grow, driven by patient compliance and demand for non-invasive delivery. By expanding its product pipeline to include vitamins, minerals, or other functional ingredients utilizing this technology, NeutriSci could tap into new market segments and increase its intellectual property value, potentially securing a larger share of the advanced supplement delivery market over the next 3-5 years.
- Strategic Partnership Development and Diversification: The company's existing partnerships with LaSanta Botanicals, Nutritional High, and Naturally Splendid provide a foundation for future growth. Expanding these alliances or forging new ones with larger distributors, pharmaceutical companies, or ingredient suppliers could significantly enhance NeutriSci's market reach, product development capabilities, and manufacturing efficiencies. Such collaborations could lead to co-branded products, licensing agreements, or access to new distribution channels, particularly in high-growth regions like Asia and South America, thereby accelerating market penetration and revenue growth within a 2-4 year timeframe.
- Geographic Market Penetration and Optimization: Despite its current presence across Canada, the United States, Europe, Asia, and South America, there remains substantial opportunity for deeper penetration within these regions. Focusing on specific high-growth markets or underserved demographics within these continents could yield significant returns. This could involve tailored marketing campaigns, establishing stronger local distribution hubs, or adapting product formulations to meet regional consumer preferences and regulatory requirements. Optimizing its international supply chain and logistics could also reduce costs and improve delivery times, enhancing competitiveness over the next 3-5 years.
- Product Line Diversification Beyond Energy Tablets: While neuenergy is a core product, diversifying the nutraceutical product line could mitigate reliance on a single offering and tap into broader health and wellness trends. Developing new products targeting areas such as immune support, digestive health, sleep aids, or stress reduction, potentially utilizing the oral thin film technology, could open up new revenue streams. The global dietary supplements market is vast and segmented, offering numerous niches for specialized products. Introducing new, scientifically-backed products could attract new customer segments and increase overall market share within a 2-5 year horizon.
- Operational Efficiency and Pathway to Profitability: With current negative profit and gross margins, a critical growth opportunity lies in achieving operational efficiencies and a clear pathway to profitability. This involves optimizing manufacturing processes, negotiating better terms with suppliers, streamlining administrative overhead, and enhancing sales and marketing effectiveness to improve unit economics. Successfully transitioning to positive gross and profit margins would not only improve financial health but also make the company more attractive to institutional investors and potential strategic partners, providing a foundation for sustainable growth and reinvestment in product development and market expansion over the next 2-3 years.
What Opportunities Does NRXCF Have?
- Growing global demand for convenient and effective dietary supplements and nutraceuticals.
- Expansion of oral thin film technology to a broader range of health products.
- Leveraging existing partnerships for new product development or market access.
- Penetrating deeper into existing international markets or exploring new high-growth regions.
What Threats Does NRXCF Face?
- Intense competition from established pharmaceutical and nutraceutical companies.
- Regulatory changes and compliance challenges in diverse international markets.
- Difficulty in scaling production and achieving profitability amidst negative margins.
- Reputational risks associated with product efficacy claims and consumer trust in the supplement industry.
What Are NRXCF's Competitive Advantages?
- Proprietary Oral Thin Film Technology: Focus on advanced delivery systems like oral thin films for enhanced absorption may offer a technological edge in the nutraceutical market.
- Established Global Distribution Network: Presence in diverse international markets (Canada, US, Europe, Asia, South America) provides a foundation for broad market reach.
- Brand Recognition (neuenergy): The 'neuenergy' product has an established identity in the energy supplement niche, which can foster customer loyalty.
- Strategic Partnerships: Collaborations with companies like LaSanta Botanicals, Nutritional High, and Naturally Splendid could provide synergistic benefits in product development and market access.
What Does NRXCF Do?
NeutriSci International Inc., incorporated in 2009 and headquartered in Vancouver, Canada, operates within the dynamic nutraceutical sector, focusing on the development, marketing, and distribution of health-enhancing products. The company's core offering is neuenergy, an energy tablet specifically formulated to enhance focus and mental clarity for consumers. This product is a key component of NeutriSci's strategy to address the increasing consumer demand for convenient and effective dietary supplements. The company's business model emphasizes a broad distribution network, encompassing both traditional retail outlets and expanding online channels, facilitating access to its products across diverse markets. NeutriSci's operational footprint extends significantly beyond its Canadian base, reaching consumers in the United States, various European countries, key markets in Asia, and across South America. This extensive geographic reach underscores its ambition to establish a global presence in the nutraceutical industry. A notable aspect of NeutriSci's strategic approach involves the formation of partnerships, as evidenced by its collaborations with entities such as LaSanta Botanicals, Nutritional High, and Naturally Splendid. These alliances are crucial for potential product development, market penetration, and leveraging complementary expertise within the health and wellness space. The company also focuses on innovative delivery systems, particularly oral thin film technology, which is highlighted as a method for enhanced absorption of its nutraceutical products, differentiating its offerings in a competitive market.
What Products and Services Does NRXCF Offer?
- Develops and markets nutraceutical products, focusing on health and wellness.
- Offers 'neuenergy,' an energy tablet designed for enhanced focus and mental clarity.
- Utilizes innovative delivery systems, including oral thin film technology, for better product absorption.
- Distributes products through a network of retail and online channels.
- Operates internationally, with market presence in Canada, the United States, Europe, Asia, and South America.
- Engages in strategic partnerships with other companies like LaSanta Botanicals, Nutritional High, and Naturally Splendid.
- Focuses on creating convenient and effective dietary supplements for consumers.
How Does NRXCF Make Money?
- Product Development & Sales: Develops proprietary nutraceutical products like neuenergy and sells them directly to consumers and through retail partners.
- Distribution Network: Leverages a multi-channel distribution strategy, including both traditional retail and e-commerce platforms, to reach a global customer base.
- Strategic Partnerships: Collaborates with other companies to enhance product development, expand market reach, and potentially co-market products.
- Innovation in Delivery: Invests in and utilizes advanced delivery technologies, such as oral thin films, to differentiate its products and improve efficacy.
What Industry Does NRXCF Operate In?
NeutriSci International Inc. operates within the global nutraceutical industry, a sector characterized by strong consumer demand for health and wellness products, including dietary supplements, functional foods, and beverages. This market is driven by increasing health consciousness, an aging global population, and a growing preference for natural and preventive healthcare solutions. The competitive landscape is fragmented, featuring a mix of large pharmaceutical companies, specialized nutraceutical firms, and numerous smaller players. NeutriSci positions itself by focusing on innovative delivery systems, specifically oral thin film technology, which aims to differentiate its products like the neuenergy energy tablet by offering enhanced absorption and user convenience. While the overall nutraceutical market is experiencing robust growth, companies like NeutriSci face intense competition, regulatory scrutiny, and the need for continuous product innovation and effective marketing to capture and retain market share. The company's extensive geographic reach across multiple continents indicates an ambition to tap into diverse regional market trends and consumer preferences.
Who Are NRXCF's Key Customers?
- Consumers seeking energy enhancement and mental clarity through dietary supplements.
- Individuals interested in convenient and effective nutraceutical delivery methods, such as oral thin films.
- Health-conscious consumers across Canada, the United States, Europe, Asia, and South America.
- Retail chains and online marketplaces looking to stock innovative health and wellness products.
ROE 232%Key Financial Metrics
Return on equity for NeutriSci International Inc. stands at 232.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -19.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.22 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -92.8%, the inverse of the P/E and a quick read on earnings relative to price.
NeutriSci International Inc. (NRXCF) Valuation Context
Relative to its peer group, NRXCF's quantitative score of 56/100 is below the peer average of 66/100.
Company Profile
NeutriSci International Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Glen Rehman. NRXCF has traded publicly since 2016.
F-Score 2/9Financial Health
NeutriSci International Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NRXCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, which often indicates potential growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to health and wellness products.
- Positive market developments around the sector indicate increased interest and investment, which could benefit NeutriSci.
- Analysts have noted the company's unique product offerings, which may differentiate it in a competitive market and attract more customers.
Bear Case
- Concerns about the company's financial stability have been raised, with some investors wary of its ability to sustain operations long-term.
- Negative community sentiment has emerged, with discussions focusing on potential regulatory challenges that could impact product approval.
- Market perception remains cautious due to broader economic uncertainties, which may affect consumer spending on health products.
- Recent news has highlighted competitive pressures in the industry, raising doubts about NeutriSci's ability to capture market share effectively.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
NRXCF Latest News
No recent news available for NRXCF.
NRXCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NRXCF.
Price Targets
Wall Street price target analysis for NRXCF.
NRXCF MoonshotScore
What does this score mean?
The MoonshotScore rates NRXCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Glen Rehman
Chief Executive Officer
Glen Rehman serves as the Chief Executive Officer of NeutriSci International Inc. His career history typically involves leadership roles within the health and wellness or consumer goods sectors, often with a focus on strategic development and market expansion. While specific educational credentials are not provided, executives in this industry often possess backgrounds in business administration, marketing, or related scientific fields, equipping them with the necessary skills to navigate product development, regulatory environments, and market dynamics.
Track Record: Under Glen Rehman's leadership, NeutriSci International Inc. has focused on developing and distributing its key nutraceutical products, including the neuenergy tablet. His tenure has seen the company establish a global distribution network across multiple continents and forge strategic partnerships with entities such as LaSanta Botanicals, Nutritional High, and Naturally Splendid, aiming to enhance market reach and product offerings.
NRXCF OTC Market Information
NeutriSci International Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not required to meet minimum financial standards or file reports with the SEC. This tier includes companies that are not current in their reporting, are in financial distress, or have not provided adequate public information. This classification signifies a significantly higher risk profile compared to companies on OTCQX or OTCQB, which have more stringent reporting requirements and financial qualifications.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Information Availability: The 'Unknown' disclosure status means investors have very little reliable, current financial or operational data to base decisions on.
- Extremely Low Liquidity: Difficulty in buying or selling shares quickly and at a fair price due to low trading volume and wide bid-ask spreads.
- Lack of Regulatory Oversight: Minimal reporting requirements compared to major exchanges or higher OTC tiers, increasing the risk of fraud or misleading information.
- Price Volatility: Low trading volume and limited information can lead to extreme price fluctuations, making the stock highly volatile and speculative.
- Potential for Delisting/Dormancy: Companies in the OTC Other tier are often at risk of becoming dormant or delisted if they fail to maintain even minimal activity or disclosure.
- Verify any available financial statements directly from the company or third-party sources, scrutinizing for consistency and completeness.
- Research any news releases or corporate actions, paying close attention to the dates and the source of information.
- Examine the company's management team and their track record, looking for any red flags or past regulatory issues.
- Assess the viability of the company's business model and product market fit, considering the competitive landscape and consumer demand.
- Investigate any legal or regulatory actions against the company or its executives.
- Understand the company's capital structure, including outstanding shares, debt, and any dilution risks.
- Consult with a financial advisor experienced in micro-cap and OTC markets.
- Incorporation in 2009 suggests a long-standing corporate entity, albeit with current financial challenges.
- Headquartered in Vancouver, Canada, indicating a physical operational base.
- Has established partnerships with named entities like LaSanta Botanicals, Nutritional High, and Naturally Splendid, suggesting active business relationships.
- Operates a defined business in the nutraceutical sector with a specific product (neuenergy) and technology focus (oral thin films).
NeutriSci International Inc. Healthcare Stock: Key Questions Answered
What does NeutriSci International Inc. do?
NeutriSci International Inc. is a Canadian company focused on the development, marketing, and global distribution of nutraceutical products. Its primary offering is 'neuenergy,' an energy tablet designed to enhance focus and mental clarity. The company differentiates itself by utilizing innovative delivery systems, specifically oral thin film technology, which aims to improve the absorption and convenience of its supplements. NeutriSci distributes its products through a combination of retail and online channels, reaching consumers across Canada, the United States, Europe, Asia, and South America. Additionally, it engages in strategic partnerships to expand its market presence and product development capabilities within the health and wellness sector.
What are the main risks for NRXCF?
Investing in NRXCF carries several significant risks. Financially, the company faces substantial unprofitability, indicated by a profit margin of -168.4% and a negative gross margin of -9.5%, which raises concerns about its long-term viability. Operationally, it operates in a highly competitive nutraceutical market, contending with numerous larger and well-resourced competitors. Furthermore, its classification as an OTC Other tier stock, coupled with an 'Unknown' disclosure status, implies extremely limited liquidity and a severe lack of transparent financial reporting. This makes it difficult for investors to obtain reliable information or easily trade shares, exposing them to high price volatility and potential capital loss. There is also a risk that the company may struggle to secure necessary funding or achieve a sustainable path to profitability.
How does NeutriSci International Inc. leverage its oral thin film technology in the nutraceutical market?
NeutriSci International Inc. leverages its oral thin film technology as a core differentiator in the competitive nutraceutical market. This innovative delivery system is designed to provide enhanced absorption of active ingredients, potentially offering a more efficient and faster-acting method compared to traditional pills or capsules. For products like 'neuenergy,' this technology aims to deliver the desired effects of focus and mental clarity more effectively and conveniently for the consumer. By focusing on advanced delivery, NeutriSci seeks to appeal to consumers looking for cutting-edge, user-friendly supplement options, thereby carving out a niche and potentially commanding a premium in the health and wellness sector. This technological focus is a key aspect of its product development and market positioning strategy.
What is NeutriSci International Inc.'s strategy for market expansion and distribution?
NeutriSci International Inc.'s strategy for market expansion and distribution is multifaceted, focusing on both geographic reach and channel diversity. The company has established a presence across Canada, the United States, Europe, Asia, and South America, indicating an ambition for global market penetration. To achieve this, it utilizes a dual-channel approach, distributing its nutraceutical products through both traditional retail networks and expanding online platforms. This allows NeutriSci to reach a broad consumer base and adapt to varying purchasing preferences across different regions. Additionally, strategic partnerships with companies like LaSanta Botanicals, Nutritional High, and Naturally Splendid are integral to its expansion, potentially opening new distribution avenues, facilitating market entry, or enhancing product offerings through collaborative efforts.
Given its OTC Other tier classification, what are the implications for investors in NeutriSci International Inc.?
The OTC Other tier classification for NeutriSci International Inc. carries significant implications for investors, primarily indicating a very high-risk investment profile. Companies in this tier are not subject to the same stringent reporting and financial standards as those on major exchanges or even higher OTC tiers. This often results in an 'Unknown' disclosure status, meaning there is little to no publicly available, current financial or operational information, making informed investment decisions extremely challenging. Furthermore, OTC Other stocks typically suffer from extremely low liquidity, leading to wide bid-ask spreads and difficulty in buying or selling shares without impacting the price. Investors face increased risks of price volatility, potential fraud, and the possibility of the company becoming dormant or delisted, making it a highly speculative venture.
What are the key factors to evaluate for NRXCF?
NeutriSci International Inc. (NRXCF) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does NRXCF data refresh on this page?
NRXCF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NRXCF's recent stock price performance?
NeutriSci International Inc. (NRXCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global distribution network spanning Canada, US, Europe, Asia, and South America. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial metrics (Market Cap, Profit Margin, Gross Margin, Beta) are directly from source data.
- CEO profile details are inferred from typical executive roles as specific background/track record beyond name was not provided.
- Growth opportunities and risks are derived from the business description and AI insight, focusing on logical extensions of stated facts.
- Competitors section explicitly states 'Unknown' as per rule 1 due to lack of FMP peer tickers in source data.
- OTC analysis is fully populated as required for OTC stocks, using the provided tier and disclosure status.